Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBITDA (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBITDA for 16 consecutive years, with $272000.0 as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 101.19% to $272000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.1 million, a 84.17% increase, with the full-year FY2025 number at -$9.1 million, up 84.17% from a year prior.
  • EBITDA was $272000.0 for Q4 2025 at Anika Therapeutics, up from -$2.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $6.7 million in Q2 2021 to a low of -$62.4 million in Q4 2023.
  • A 5-year average of -$8.1 million and a median of -$3.8 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 189.75% in 2021, then tumbled 5623.08% in 2022.
  • Anika Therapeutics' EBITDA stood at -$6.2 million in 2021, then soared by 37.76% to -$3.9 million in 2022, then tumbled by 1518.55% to -$62.4 million in 2023, then surged by 63.21% to -$22.9 million in 2024, then soared by 101.19% to $272000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EBITDA are $272000.0 (Q4 2025), -$2.5 million (Q3 2025), and -$2.6 million (Q2 2025).